Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

UNBS-5162

A CXCL chemokines receptor antagonist
Catalog #: B2587
SKU-Size Size Price Qty
B2587-5 5 mg
$95.00
B2587-25 25 mg
$375.00
More Sizes Get Quote

Product Details

Alternate Name UNBS 5162, 1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea, UNBS5162
Peptide Sequence N/A
Appearance Yellow solid
CAS # 956590-23-1
Molecular Formula C₁₇H₁₈N₄O₃
Molecular Weight 326.35
Purity ≥98% by HPLC
Solubility in DMSO
SMILES O=C(C1=CC(NC(N)=O)=CC2=C1C3=CC=C2)N(CCN(C)C)C3=O
InChi InChI=1S/C17H18N4O3/c1-20(2)6-7-21-15(22)12-5-3-4-10-8-11(19-17(18)24)9-13(14(10)12)16(21)23/h3-5,8-9H,6-7H2,1-2H3,(H3,18,19,24)
InChi Key WCKZRLOUKYFJDY-UHFFFAOYSA-N
PubChem CID 16048966
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

UNBS5162 is a novel naphthalimide that suppresses the expression of CXCL chemokines. In vitro exposure of PC-3 prostate cancer cells to 1 µM UNBS5162 for five successive days is shown to decrease the expression of proangiogenic CXCL chemokines. UNBS5162 also displays antiangiogenic properties in vivo in an orthotopic PC-3 model.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.